English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  To examine variation between general practices in the prescription of lipid‐lowering treatment to people with screen‐detected Type 2 diabetes, and associations with practice and participant characteristics and risk of cardiovascular events and all‐cause mortality.    Methods  Observational cohort analysis of data from 1533 people with screen‐detected Type 2 diabetes aged 40–69 years from the   ADDITION ‐Denmark  study. One hundred and seventy‐four general practices were cluster randomized to receive: (1) routine diabetes care according to national guidelines (623 individuals), or (2) intensive multifactorial target‐driven management (910 individuals). Multivariable logistic regression was used to quantify the association between the proportion of individuals in each practice who redeemed prescriptions for lipid‐lowering medication in the two years following diabetes diagnosis and a composite cardiovascular disease ( CVD ) outcome, adjusting for age, sex, prevalent chronic disease, baseline  CVD  risk factors, smoking and lipid‐lowering medication, and follow‐up time.    Results  The proportion of individuals treated with lipid‐lowering medication varied widely between practices (0–100%). There were 118  CVD  events over 9431 person‐years of follow‐up. For the whole trial cohort, the risk of  CVD  was significantly higher in practices in the lowest compared with the highest quartile for prescribing lipid‐lowering medication [adjusted odds ratio ( OR ) 3.4, 95% confidence interval ( CI ) 1.6–7.3]. Similar trends were found for all‐cause mortality.    Conclusions  More frequent prescription of lipid‐lowering treatment was associated with a lower incidence of  CVD  and all‐cause mortality. Improved understanding of factors underlying practice variation in prescribing may enable more frequent use of lipid‐lowering treatment. The results highlight the benefits of intensive treatment of people with screen‐detected diabetes (Clinical Trials Registry No; NCT 00237549).

diabetic medicine

Variation in prescribing of lipid‐lowering medication in primary care is associated with incidence of cardiovascular disease and all‐cause mortality in people with screen‐detected diabetes: findings from the   ADDITION ‐Denmark  trial